The global demand for Antidiabetics Market is presumed to reach the market size of nearly USD 210.33 MN by 2028 from USD 96.95 MN in 2021 with a CAGR of 11.7% under the study period 2022 - 2028.
Antidiabetic drugs are medicines introduced to stabilise and control blood glucose levels in people suffering from diabetes. Antidiabetic drugs are mainly used to manage diabetes and aid diabetic patients in maintaining their condition and lowering their risk of developing diabetes. Antidiabetic drugs include insulin, pramlintide, byetta,victoza and oral hypoglycemics (tablets).
Market Dynamics
The growing rates of diabetics and rising healthcare expenditure are the fundamental factors that are spurring the growth of the global antidiabetics market. Also, the global prevalence of obesity is expected to serve the antidiabetics market as a driver. Moreover, various significant participants are adopting business growth strategies such as R&D investments and product launches, boosting the antidiabetics market's growth. Furthermore, several campaigns for awareness and education programs created by associations and diabetes societies to raise awareness levels and provide information about diabetes control will stimulate further growth. However, the cost of insulin may limit antidiabetic market growth to some extent.
The research report covers Porter's Five Forces Model, Market Attractiveness Analysis, and Value Chain analysis. These tools help to get a clear picture of the industry's structure and evaluate the competition attractiveness at a global level. Additionally, these tools also give an inclusive assessment of each segment in the global market of antidiabetics. The growth and trends of antidiabetics industry provide a holistic approach to this study.
Market Segmentation
This section of the antidiabetics market report provides detailed data on the segments at country and regional level, thereby assisting the strategist in identifying the target demographics for the respective product or services with the upcoming opportunities.
By Product
- Insulin (Rapid Acting Analog, Long Acting Analog, Premixed insulin, Short Acting Analog, Intermediate Acting Insulin)
- Drug Class (Alpha Glucosidase Inhibitors, Biguanides, Sulphonylureas, GLP-1 (Glucagon like peptide) Agonists, DPP-IV (Dipeptidyl Peptidase) inhibitors, Meglitinides, SGLT-II (Sodium Glucose Transport Proteins) inhibitors, Thiazolidinedione)
By Patient Population
- Pediatric
- Adult
- Geriatric
By Route Of Administration
- Insulin Syringe/ Insulin Pen
- Insulin Pump
- Intravenous Infusion
- Oral
- Others
Regional Analysis
This section covers the regional outlook, which accentuates current and future demand for the Antidiabetics market across North America, Europe, Asia-Pacific, Latin America, and Middle East & Africa. Further, the report focuses on demand, estimation, and forecast for individual application segments across all the prominent regions.
Global Antidiabetics Market Share by Region (Representative Graph)
The research report also covers the comprehensive profiles of the key players in the market and an in-depth view of the competitive landscape worldwide. The major players in the antidiabetics market include AstraZeneca, Novartis AG, Johnson & Johnson, Merck & Co. Inc., Pfizer and Sanofi. This section consists of a holistic view of the competitive landscape that includes various strategic developments such as key mergers & acquisitions, future capacities, partnerships, financial overviews, collaborations, new product developments, new product launches, and other developments.
In case you have any custom requirements, do write to us. Our research team can offer a customized report as per your need.